Loading...
Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
This commentary provides the authors’ perspective on the article “Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial,” which has recently been published in The Lancet Oncology.
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Landes Bioscience
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3494633/ https://ncbi.nlm.nih.gov/pubmed/23170267 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.20591 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|